Skip to content

Remimazolam Versus Propopol Based Total Intravenous Anesthesia for Breast Surgery

Comparison Between Remimazolam Versus Propopol Based Total Intravenous Anesthesia for Breast Surgery : a Randomized Controlled Trial

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05375747
Enrollment
0
Registered
2022-05-17
Start date
2022-06-13
Completion date
2023-01-09
Last updated
2024-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotension

Brief summary

Comparison of the incidence of hypotension under remimazolam and propofol-based anesthesia in patients undergoing breast surgery under general anesthesia

Detailed description

The purpose of this study was to investigate whether remimazolam-based general anesthesia could reduce the incidence of hypotension in patients undergoing breast surgery under general anesthesia compared to propofol-based general anesthesia. The purpose of this study is to establish and test the hypothesis that the incidence of hypotension under general anesthesia based on remimazolam will be less than that of propofol based general anesthesia. In addition, this study compares the proportion of patients who require a vasopressor, the time taken for anesthesia induction, the time to recover from anesthesia, postoperative pain, the incidence of postoperative nausea and vomiting, the quality of postoperative recovery, and patient satisfaction.

Interventions

DRUGRemimazolam

For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of remimazolam and remifentanil.

DRUGPropofol

For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of propofol and remifentanil.

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients over the age of 19 undergoing elective breast cancer surgery under general anesthesia at Seoul National University Hospital

Exclusion criteria

* patients with acute narrow-angle glaucoma/ shock or coma/ acute alcohol poisoning/ sleep apnea/ alcohol or drug dependency/ severe or acute respiratory failure/ galactose intolerance/ Lapp lactase deficiency/ glucose galactose malabsorption/ severe hypersensitivity to dextran. * Patients with myasthenia gravis/ pulmonary heart disease/ chronic obstructive pulmonary disease/ bronchial asthma * Patients with cardiovascular diseases such as ischemic heart disease/ coronary artery disease/ angina pectoris/ myocardial infarction/ atherosclerosis/ arrhythmia/ cerebrovascular disease/ and stroke * Patients with chronic renal failure * Patients with severe hepatic impairment (Child Pugh class C) * Patients with American Society of Anesthesiology score III or higher * Patients with hypersensitivity to propofol and soy or peanuts * Epilepsy patients * Patient with fat metabolism abnormality * Patients with high intracranial pressure * Pregnant woman * Patients unable to use supraglottic airway due to poor dental condition * In cases that the researcher judges to be unsuitable for this clinical trial

Design outcomes

Primary

MeasureTime frameDescription
Hypotension incidencefrom induction of anesthesia to end of surgeryIncidence of hypotension (MAP \<65 mmHg) from induction of anesthesia to end of surgery

Secondary

MeasureTime frameDescription
Incidence of bradycardiafrom induction of anesthesia to end of surgeryIncidence of bradycardia during operation, bradycardia is defined as heart rate less than 50
Severity of injection painAt the start of induction of general anesthesiaSeverity of injection pain of sedative(propofol or remimazolam depending on group assignment) during induction of anethesia: none/ mild/ moderate/ severe
Incidence of intraoperative awarenessfrom induction of anesthesia to end of surgeryIncedence of intraoperative awareness during operation
Incidence of intraoperative body movementfrom induction of anesthesia to end of surgeryIncidence of intraoperative body movement during operation
Use of vasopressorfrom induction of anesthesia to end of surgeryProportion of patients using vasopressors due to hypotension from induction of anesthesia to completion of surgery
Number of occurrences of hypotension during surgeryfrom induction of anesthesia to end of surgeryNumber of occurrences of hypotension during surgery
Type of vasopressor usedfrom induction of anesthesia to end of surgeryType of vasopressor used
Total dose of vasopressor usedfrom induction of anesthesia to end of surgeryTotal dose of vasopressor used
Blood pressurefrom induction of anesthesia to end of surgeryBlood pressure during operation, noninvasive blood pressure is measured at lower leg
Heart ratefrom induction of anesthesia to end of surgeryHeart rate during operation
Saturation of percutaneous oxygen (SpO2)from induction of anesthesia to end of surgerySaturation of percutaneous oxygen (SpO2) during operation
Patient State Index (PSi)from induction of anesthesia to end of surgeryPatient State Index (PSi) during operation
Incidence of use of rescue sedative agentsfrom induction of anesthesia to end of surgeryIncidence of use of any kinds of rescue sedative agents
Time from the end of administration of sedative to eye openingfrom end of administration of sedative to eye openingTime from the end of administration of sedative(propofol or remimazolam depending on group assignment) to eye opening
Time from the end of administration of sedative to response to verbal commandfrom end of administration of sedative to response to verbal commandTime from the end of administration of sedative(propofol or remimazolam depending on group assignment) to response to verbal command
Time from the end of administration of sedative to supraglottic airway removalfrom end of administration of sedative to supraglottic airway removalTime from the end of administration of sedative(propofol or remimazolam depending on group assignment) to supraglottic airway removal
Duration of post anesthesia care unit stayFrom entering post anesthesia care unit until leaving, post-operatively 1 hour averageDuration of post anesthesia care unit stay
Total analgesic consumption for 24 hours after surgeryFor 24 hours after the end of surgeryTotal analgesic consumption for 24 hours after surgery
Numeric rating scale score in the recovery room immediately after surgeryImmediate after end of surgeryNumeric rating scale score in the recovery room immediately after surgery, Numeric rating scale: 0 points for no pain, 10 points for the worst pain imaginable / The higher the number, the more severe the pain
Incidence of nausea and vomiting within 24 hours after surgerywithin 24 hours after surgeryIncidence of nausea and vomiting within 24 hours after surgery
Severity of nausea and vomiting within 24 hours after surgerywithin 24 hours after surgerySeverity of nausea and vomiting within 24 hours after surgery: none,. mild, moderate, severe
Subjective sleep quality on the day of surgeryDuring the day of surgerySubjective sleep quality on the day of surgery, Score out of 10, the higher the number, the better the quality of sleep
Patient satisfaction with anesthesiaThe day of operationPatient satisfaction with anesthesia, Score out of 10, the higher the number, the better the quality of sleep
Hospital length of stayFrom administration to discharge, average 4 daysHospital length of stay
15 item Quality of Recovery24 hours after surgery15 item Quality of Recovery: 15-item questionnaire about the degree of recovery after surgery, 10 points per question, total 150 points
T ime from start of administration of sedative drug to loss of consciousnessfrom induction of anesthesia to loss of consciousnessT ime from start of administration of sedative drug to loss of consciousness

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026